- Published at
- by gurufocus.com
mixed
mixed
News for Oncolytics Biotech Inc. (ONC.TO)
- Published at
- by gurufocus.com
positivepositiveOncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
PR NewswireSAN DIEGO and CALGARY, AB, April 10, 2025 SAN DIEGO and CALGARY, AB, April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TS- Published at
- by gurufocus.com
positivepositiveOncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital | ONCY Stock News
Oncolytics Biotech (ONCY) secures up to US$20 million funding through a share purchase agreement with Alumni Capital LP. Oncolytics maintains control ov- Published at
- by gurufocus.com
neutralneutralOncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
PR NewswireSAN DIEGO and CALGARY, AB, April 10, 2025 SAN DIEGO and CALGARY, AB, April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TS- Published at
- by gurufocus.com
negativenegativeOncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers | ONCY Stock News
Oncolytics Biotech Inc. (NASDAQ: ONCY) discussed at H.C. Wainwright event for oncolytic immunotherapies in breast and pancreatic cancers. Experts highlighte- Published at
- by gurufocus.com
mixedmixedWhy the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
PR NewswireVANCOUVER, BC, March 8, 2025 USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 8, 2025 /PRNewswire/- Published at
- by gurufocus.com
positivepositiveOncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: Promising Cancer Study Results Amid Financial Challenges
Cash and Cash Equivalents: $15.9 million as of December 31, 2024.Net Cash Used in Operating Activities: $27 million for 2024, compared to $28.4 million for 202- Published at
- by gurufocus.com
positivepositiveQ4 2024 Oncolytics Biotech Inc Earnings Call Transcript
Mar 07, 2025 / 01:30PM GMTOperator Good morning, and welcome to Oncolytics Biotech's fourth-quarter and full-year 2024 conference call. (Operator Instructions)- Published at
- by seekingalpha.com
neutralneutralOncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2024 Results Conference Call March 7, 2025 8:30 AM ETCompany ParticipantsJon Patton - Director of Investor...- Published at
- by gurufocus.com
neutralneutralOncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024
PR NewswireSAN DIEGO and CALGARY, AB, March 7, 2025 BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful dat- Published at
- by gurufocus.com
mixedmixed- Published at
- by gurufocus.com
neutralneutralOncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
PR NewswireSAN DIEGO and CALGARY, AB, Feb. 25, 2025 Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ETSAN DIEGO and CALGAR- Published at
- by gurufocus.com
negativenegativeOncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
PR NewswireSAN DIEGO and CALGARY, AB, Feb. 18, 2025 Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy- Published at
- by gurufocus.com
mixedmixedAnson Funds Management LP Acquires Significant Stake in Oncolytics Biotech Inc
Significant Transaction on December 31, 2024 On December 31, 2024, Anson Funds Management LP (Trades, Portfolio) executed a noteworthy transaction by acquiring- Published at
- by gurufocus.com
neutralneutralOncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
PR NewswireSAN DIEGO and CALGARY, AB, Feb. 14, 2025 SAN DIEGO and CALGARY, AB, Feb. 14, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX:- Published at
- by gurufocus.com
neutralneutralOncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence
PR NewswireSAN DIEGO and CALGARY, AB, Feb. 7, 2025 Search for Chief Executive Officer to commence immediatelySAN DIEGO and CALGARY, AB, Feb. 7, 2025 /PRNew- Published at
- by gurufocus.com
neutralneutralRegulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data
PR NewswireSAN DIEGO and CALGARY, AB, Jan. 15, 2025 New pancreatic cancer cohort moves forward with full enrollment of 30 patients in Stage 1SAN DIEGO and- Published at
- by investing.com
mixedmixedAchievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook By Investing.com
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook- Published at
- by gurufocus.com
positivepositiveAchievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
PALM BEACH, Fla., Dec. 26, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The breast cancer drugs market is experiencing rapid expansion due to the- Published at
- by investing.com
neutralneutralOncolytics Biotech ® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data By Investing.com
Oncolytics Biotech ® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data